What is Collate?
Collate operates at the intersection of artificial intelligence and regulatory compliance, providing a specialized platform designed to automate the arduous paperwork processes inherent in drug development and medical device manufacturing. The company's technology stack addresses the critical pain points of documentation management from initial concept through to final market launch. By digitizing and automating these workflows, Collate enables life science firms to reduce time-to-market while maintaining stringent adherence to global regulatory standards. The platform serves as a foundational layer for innovation, allowing research-heavy organizations to focus on scientific breakthroughs rather than administrative bottlenecks. As the industry faces increasing pressure to accelerate development timelines, Collate's market position as an enterprise-grade automation partner becomes increasingly vital for operational efficiency.
How much funding has Collate raised?
Collate has raised a total of $125M across 2 funding rounds:
Angel/Seed
$30M
Unspecified
$95M
Angel/Seed (2025): $30M with participation from First Round Capital and Y Combinator
Unspecified (2026): $95M led by Redpoint Ventures
Key Investors in Collate
First Round Capital
First Round is an early-stage venture capital firm that helps startups tackle company building firsts through tailored programs and a vibrant community.
Y Combinator
Established in 2005, Y Combinator provides seed funding for startup businesses and acts as a primary accelerator for high-growth technology ventures.
Redpoint Ventures
Redpoint Ventures is a venture capital firm founded in 1999 that focuses on investments in early growth-stage companies across the technology landscape.
What's next for Collate?
With the successful closure of this major enterprise-level funding round, Collate is poised to scale its engineering and product development teams to meet growing demand. The strategic roadmap likely involves expanding the platform's capabilities to support more complex regulatory frameworks and integrating advanced predictive analytics to further optimize the documentation lifecycle. By utilizing this capital to deepen its market penetration, Collate aims to solidify its status as the industry standard for automated regulatory compliance. Future growth will likely focus on enhancing interoperability with existing enterprise resource planning systems, ensuring that Collate remains an indispensable asset for global life science enterprises seeking to maintain a competitive edge in a data-intensive regulatory environment.
See full Collate company page
